WO2022225384A1 - Proceso de obtención de rifapentina. con una nueva forma cristalina - Google Patents
Proceso de obtención de rifapentina. con una nueva forma cristalina Download PDFInfo
- Publication number
- WO2022225384A1 WO2022225384A1 PCT/MX2021/050020 MX2021050020W WO2022225384A1 WO 2022225384 A1 WO2022225384 A1 WO 2022225384A1 MX 2021050020 W MX2021050020 W MX 2021050020W WO 2022225384 A1 WO2022225384 A1 WO 2022225384A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rifapentine
- water
- crystalline form
- pure
- mixture
- Prior art date
Links
- WDZCUPBHRAEYDL-GZAUEHORSA-N rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 title claims abstract description 68
- 229960002599 rifapentine Drugs 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000000203 mixture Substances 0.000 claims abstract description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims abstract description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 8
- 229930040373 Paraformaldehyde Natural products 0.000 claims abstract description 8
- 229920002866 paraformaldehyde Polymers 0.000 claims abstract description 8
- 229960000583 acetic acid Drugs 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 5
- BTVYFIMKUHNOBZ-ODRIEIDWSA-N Rifamycin S Chemical compound O=C1C(C(O)=C2C)=C3C(=O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O BTVYFIMKUHNOBZ-ODRIEIDWSA-N 0.000 claims abstract description 4
- BTVYFIMKUHNOBZ-ZDHWWVNNSA-N Rifamycin S Natural products COC1C=COC2(C)Oc3c(C)c(O)c4C(=O)C(=CC(=O)c4c3C2=O)NC(=O)C(=C/C=C/C(C)C(O)C(C)C(O)C(C)C(OC(=O)C)C1C)C BTVYFIMKUHNOBZ-ZDHWWVNNSA-N 0.000 claims abstract description 4
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 4
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 4
- 239000012362 glacial acetic acid Substances 0.000 claims abstract description 4
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 3
- 238000005406 washing Methods 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000000047 product Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 238000013019 agitation Methods 0.000 claims description 2
- 239000012043 crude product Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000011541 reaction mixture Substances 0.000 claims description 2
- 238000012512 characterization method Methods 0.000 abstract description 3
- 238000010438 heat treatment Methods 0.000 abstract description 3
- QYHRIASMJNLWHJ-UHFFFAOYSA-N 4-cyclopentylpiperazin-1-amine Chemical compound C1CN(N)CCN1C1CCCC1 QYHRIASMJNLWHJ-UHFFFAOYSA-N 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 239000013078 crystal Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960001225 rifampicin Drugs 0.000 description 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 229930189077 Rifamycin Natural products 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- YAXMCEWRTZAGIM-DSTWUDMISA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-26-[(E)-(4-cyclopentylpiperazin-1-yl)iminomethyl]-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate hydrochloride Chemical compound Cl.CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(CC4)C4CCCC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C YAXMCEWRTZAGIM-DSTWUDMISA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960003292 rifamycin Drugs 0.000 description 1
- HJYYPODYNSCCOU-ODRIEIDWSA-N rifamycin SV Chemical compound OC1=C(C(O)=C2C)C3=C(O)C=C1NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@H](C)[C@@H](OC)\C=C\O[C@@]1(C)OC2=C3C1=O HJYYPODYNSCCOU-ODRIEIDWSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Definitions
- the invention relates to the preparation of a new crystalline form of rifapentine.
- the present invention relates to the preparation of a new pure crystalline form of rifapentine, the new pure crystalline form as such, and to pharmaceutical formulations containing it.
- Rifapentine is a rifamycin that is characterized by having a greater inhibition potential against the bacterium Mycobacterium tuberculosis and by having a longer half-life than rifampicin.
- Rifapentine is the generic name of an antibiotic described in US Patent 4,002,752, particularly useful in the treatment of acute pulmonary infections, M. Tsukamura et al., Kekkaku (Tuberculosis, Japan), 1986, 61/12, (633-639 ); PHYSICAL EDUCATION. Varaldo et al., Antimicrobial Agents Chemother. (USA), 1985, 4/27, (615-618); Yi Lu et al., Chin. J. Antib. (China), 1987, 12/5, (341-344) and L.B. Heifets et al., Am. Rev. Respir. Dis 1990; 141, 626-360, describe the bactericidal activity of rifapentine against Mycobacterium avium.
- Rifapentine obtained according to the process described in US 4,002,752 is generally a mixture of different solid forms. These different forms show different stability, formulability and bioavailability characteristics. In general they are solvates or mixtures of solvates, depending on the "crystallization" solvent or solvents. It is mentioned that a pure amorphous or crystalline form is obtained through the process, but it is not characterized. In publication WO 90/00553, January 25, 990, processes for obtaining Rifapentine salts are described: hydrochloride or hydrobromide, which have 2 crystalline forms and an amorphous form.
- Form I is obtained by crystallization from methanol
- Form II is obtained by crystallization from Acetone and re-crystallization from
- Amorphous form obtained by crystallization of ethyl acetate and precipitation in chloroform/ethyl ether.
- Form I is obtained by crystallization from methanol.
- Form II is obtained by crystallization from Acetone.
- Amorphous form obtained by precipitation in Chloroform/Ethyl ether, without diffraction data.
- Figure 3 is a perspective view of the molecular structure of Rifapentine.
- the crystal is packaged as a stack.
- the five-membered ring of furan and naphthalene are coplanar.
- the six-membered ring of piperazine and the five-membered ring of cyclopentyl have a chair conformation.
- the structure of Rifapentine is Monoclinic. In the Diffractogram, sharp peaks are observed at diffraction angles (2° Q): 5.57°, 6.65°, 7.9°, 10.29°, 14.83°, 15.66°, 21.28° and 22.74°.
- Rifapentine Two crystalline forms of Rifapentine are described in A Novel Inhalable Form of Rifapentine. Journal of Pharmaceutical Sciences, 103: 1411-1421, (2014).
- 4 mg/mL of Rifapentine is dissolved in a co-solvent system of Acetone and deionized water (1:1, v/v).
- Acetone is removed by heating to 67°, obtaining an aqueous suspension of crystalline Rifapentine.
- the suspension was homogenized at 10,000 rpm for 2 minutes to obtain a small and uniform crystal size. This suspension was spray dried.
- amorphous Rifapentin was prepared by dissolving 4 mg/mL of Methanol and spray-dried.
- the X-ray diffractogram showed multiple peaks of strong intensity and a typical "halo" pattern for crystalline (upper) and amorphous (lower) Rifapentine powder.
- New and stable forms of rifapentine are still needed to meet stability requirements under both normal storage and formulation conditions in order to optimize preparation, formulation, storage and administration steps in an accurate, reliable and standardized manner. Furthermore, a stable and well-defined crystalline form of an active substance is often a precondition and even a guarantee of a reliable and precise bioavailability pattern that is not subject to relevant variations between batches.
- Figure 2 Shows the Rifapentine synthesis scheme according to the present invention.
- Figure 3 Illustrates the molecular configuration of Rifapentine and the atom numbering scheme.
- an object of this invention is a pure crystalline form of rifapentine, which is obtained in pure form according to the process of the invention.
- pure crystalline form it is intended that the crystalline form described is a solid consisting of rifapentine crystals.
- This pure crystalline form proves to be stable and non-hygroscopic under the usual storage conditions and in the usual manipulations of the formulation. Stability throughout the formulation and storage process is of importance for reliable bioavailability of the administered dose.
- Another object of the invention is the process for preparing the pure crystalline form of rifapentine.
- the rifapentine synthesis process object of the present invention consists of mixing Dimethylformamide, tert-Butylamine and paraformaldehyde; add Rifamycin S and glacial Acetic Acid at 40°C ⁇ 5; add paraformaldehyde and heat at 62-68°C for 2 hours.
- the crude Rifapentine yield is 87+ 5% with a purity of 99.00%.
- the crude product is purified by dissolving the solid in a mixture of Ethanol and water (6:1) and heating under reflux for about 1 hour. The mixture is cooled to 15-20°C and the pure Rifapentine is filtered, washed with a mixture of Ethanol/Water (l:l) and a second wash with 2 volumes of Water, squeezed and dried at 60-65 ° C with vacuum.
- a repulping process is carried out in water, mixing pure Rifapentine with 8 volumes of water, under agitation, filtering and washing with 1 volume of water. It is squeezed out and dried under vacuum at 60°C for 16 hours. Pure Rifapentine is obtained with a yield of 73+ 3% and a purity of 99.50%.
- Rifapentine pure crystalline form can be formulated into various pharmaceutical dosage forms, such forms include oral solid forms such as capsules, tablets, dragees, film-coated tablets, sugar-coated tablets, hard gelatin capsules, soft elastic capsules and the like. . These forms may contain the pure rifapentine crystalline form obtained according to the process in pharmaceutically effective doses in powder form mixed with the usual inert excipients such as binders, disintegrants, lubricants and preservatives. These additives are essentially the same as those that can be used in formulations of similar antibiotics, for example rifampin.
- compositions suitable for oral administration or external applications include solutions, syrups, suspensions, emulsions, and the like. Also in these cases, the method and ingredients normally used for the formulation of similar antibiotics, eg rifampin, can be used successfully.
- Pharmaceutical dosage forms for parenteral administration are also included in this particular aspect of the invention. These pharmaceutical dosage forms include preparations suitable for intramuscular or intravenous administration which may optionally be formulated as a dry powder for reconstitution before use.
- the pure crystalline form of rifapentine can also be administered for the use of pharmaceutical forms such as aerosols, ointments and suppositories.
- the manufacture of pharmaceutical dosage forms containing the pure crystalline form of rifapentine can be accomplished by commonly known procedures, see, for example: Remington's Pharmaceuticals Sciences, 17th Edition, (1985) Mack Publishing Co., East, Pennsylvania 18042 .
- the product is filtered and washed with 400 mL of an Ethanol/water mixture (1:1), the product is expressed for 60 minutes and vacuum dried at 60-65°C for 16 hours.
- Ethanol and water mixture 6 volumes are added to crude Rifapentine and heated at reflux for 60 minutes. It is then cooled to 15-20°C, maintaining this temperature for 30 minutes. Pure Rifapentin is filtered, washed with 2 volumes of Ethanol/Water mixture (1:1), a second wash is carried out with 2 volumes of Water, it is squeezed for 60 minutes and dried at 60-65°C. under vacuum for 16 hours.
- Figures 2 to 6 show the comparison of the X-ray powder diffraction pattern of the crystalline form of Rifapentine of the present invention with the reflections of the crystalline forms reported in WO 90/00553, WO 92/00302, Zhou, Li & Zheng, J. Molecular Structure (2010) and Zhou, Li & Zheng, Chem.Eng. China (2010), where it is shown that the crystalline form of Rifapentine of the present invention Form I does not correspond to any of the diffraction patterns reported in the state of the art.
- the "monoclinic" crystalline form reported in the publications of Zhou, K. et al. shows a variation in the position of 2-Theta greater than 0.2 degrees, compared to the diffraction pattern of the crystalline form of Rifapentine. according to the present invention.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/MX2021/050020 WO2022225384A1 (es) | 2021-04-21 | 2021-04-21 | Proceso de obtención de rifapentina. con una nueva forma cristalina |
US18/555,776 US20240199642A1 (en) | 2021-04-21 | 2021-04-21 | Method for obtaining rifapentine with a new crystalline form |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/MX2021/050020 WO2022225384A1 (es) | 2021-04-21 | 2021-04-21 | Proceso de obtención de rifapentina. con una nueva forma cristalina |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022225384A1 true WO2022225384A1 (es) | 2022-10-27 |
Family
ID=83723045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/MX2021/050020 WO2022225384A1 (es) | 2021-04-21 | 2021-04-21 | Proceso de obtención de rifapentina. con una nueva forma cristalina |
Country Status (2)
Country | Link |
---|---|
US (1) | US20240199642A1 (es) |
WO (1) | WO2022225384A1 (es) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4002752A (en) * | 1975-03-05 | 1977-01-11 | Gruppo Lepetit S.P.A. | Piperazinylimino rifamycins |
WO1990000553A1 (en) * | 1988-07-13 | 1990-01-25 | Gruppo Lepetit S.P.A. | Rifapentine hydrohalides |
WO1992000302A1 (en) * | 1990-06-29 | 1992-01-09 | Gruppo Lepetit S.P.A. | Pure crystalline form of rifapentine |
CN103951677A (zh) * | 2014-03-17 | 2014-07-30 | 四川省长征药业股份有限公司 | 利福喷丁的制备方法 |
CN111018886A (zh) * | 2019-12-20 | 2020-04-17 | 无锡福祈制药有限公司 | 一种高纯度利福喷丁的制备方法 |
-
2021
- 2021-04-21 US US18/555,776 patent/US20240199642A1/en active Pending
- 2021-04-21 WO PCT/MX2021/050020 patent/WO2022225384A1/es active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4002752A (en) * | 1975-03-05 | 1977-01-11 | Gruppo Lepetit S.P.A. | Piperazinylimino rifamycins |
WO1990000553A1 (en) * | 1988-07-13 | 1990-01-25 | Gruppo Lepetit S.P.A. | Rifapentine hydrohalides |
WO1992000302A1 (en) * | 1990-06-29 | 1992-01-09 | Gruppo Lepetit S.P.A. | Pure crystalline form of rifapentine |
CN103951677A (zh) * | 2014-03-17 | 2014-07-30 | 四川省长征药业股份有限公司 | 利福喷丁的制备方法 |
CN111018886A (zh) * | 2019-12-20 | 2020-04-17 | 无锡福祈制药有限公司 | 一种高纯度利福喷丁的制备方法 |
Non-Patent Citations (2)
Title |
---|
CHAN JOHN G.Y., DUKE COLIN C., ONG HUI XIN, CHAN JOSEPH C.Y., TYNE ANNELIESE S., CHAN HAK-KIM, BRITTON WARWICK J., YOUNG PAUL M., : "A Novel Inhalable Form of Rifapentine", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN CHEMICAL SOCIETY AND AMERICAN PHARMACEUTICAL ASSOCIATION, US, vol. 103, no. 5, 1 May 2014 (2014-05-01), US , pages 1411 - 1421, XP093000134, ISSN: 0022-3549, DOI: 10.1002/jps.23911 * |
ZHOU, K. ; LI, J. ; ZHENG, D.S.: "Growth, characterization and crystal structure analysis of rifapentine", JOURNAL OF MOLECULAR STRUCTURE, ELSEVIER AMSTERDAM, NL, vol. 983, no. 1-3, 1 November 2010 (2010-11-01), NL , pages 27 - 31, XP027430398, ISSN: 0022-2860, DOI: 10.1016/j.molstruc.2010.08.023 * |
Also Published As
Publication number | Publication date |
---|---|
US20240199642A1 (en) | 2024-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008253696B2 (en) | Formoterol tartrate process and polymorph | |
EP0548114B1 (en) | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions | |
CN109311832B (zh) | 沃替西汀的帕莫酸盐及其晶型 | |
EP3243824A1 (en) | Solid forms of ibrutinib free base | |
MX2011010657A (es) | Proceso para la preparacion de sales de pirrolidinio. | |
WO2007013086A1 (en) | Novel polymorphs of tenofovir disoproxil fumarate | |
US20050080255A1 (en) | Crystalline cefdinir potassium dihydrate | |
JP2017025068A (ja) | エルタペネムナトリウムの結晶形およびその調製方法 | |
CN107522655B (zh) | 一种异烟肼、吡嗪酰胺与富马酸的三元共晶及其制备方法 | |
ES2911894T3 (es) | Nuevas formas de sal y estado sólido de escitalopram | |
EP0440642B1 (en) | Rifapentine hydrohalides | |
TWI808069B (zh) | [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式 | |
CN112538123B (zh) | 一种舒更葡糖钠晶型m | |
CA2561635C (en) | New crystalline form of 8-cyano-1-cyclopropyl-7-(1s,6s-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | |
WO2022225384A1 (es) | Proceso de obtención de rifapentina. con una nueva forma cristalina | |
CN112538124B (zh) | 一种舒更葡糖钠晶型 | |
JP2008174551A (ja) | ラベプラゾールナトリウムの結晶形態 | |
US20220119415A1 (en) | Solid forms of [(1s)-1-[(2s,4r,5r)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate | |
US12012420B2 (en) | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate | |
ES2392464T3 (es) | Nuevas formas cristalinas de atovaquona | |
WO2017094204A1 (en) | Luliconazole as anti-acanthamoeba agent and method for producing the same | |
ES2973874T3 (es) | Formas sólidas de ceftolozano y procesos para su preparación | |
CN105461739B (zh) | 结晶头孢嗪脒钠及其制备方法和用途 | |
JP2954956B2 (ja) | 結晶(5r,6s)‐2‐カルバモイルオキシメチル‐6‐[(1r)‐ヒドロキシエチル]‐2‐ペネム‐カルボン酸及びその医薬処方物 | |
CA3041134A1 (en) | Novel salts of nilotinib and crystalline forms thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21938055 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18555776 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/012416 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21938055 Country of ref document: EP Kind code of ref document: A1 |